328 related articles for article (PubMed ID: 36066162)
21. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
[TBL] [Abstract][Full Text] [Related]
22. m6A-immune-related lncRNA prognostic signature for predicting immune landscape and prognosis of bladder cancer.
Feng ZH; Liang YP; Cen JJ; Yao HH; Lin HS; Li JY; Liang H; Wang Z; Deng Q; Cao JZ; Huang Y; Wei JH; Luo JH; Chen W; Chen ZH
J Transl Med; 2022 Oct; 20(1):492. PubMed ID: 36309694
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive Analysis of N6-Methyladenosine-Related lncRNA Signature for Predicting Prognosis and Immune Cell Infiltration in Patients with Colorectal Cancer.
Zhao Z; Yang YB; Li XY; Li XG; Chu XD; Lin ZB; Zhang YR; Guo YG; Ding H; Pan YL; Wang L; Pan JH
Dis Markers; 2021; 2021():8686307. PubMed ID: 34745388
[TBL] [Abstract][Full Text] [Related]
24. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.
Zhang P; Xu K; Wang J; Zhang J; Quan H
BMC Cancer; 2021 Dec; 21(1):1285. PubMed ID: 34852770
[TBL] [Abstract][Full Text] [Related]
25. Integrated analysis on the N6-methyladenosine-related long noncoding RNAs prognostic signature, immune checkpoints, and immune cell infiltration in clear cell renal cell carcinoma.
Qiu Y; Wang X; Fan Z; Zhan S; Jiang X; Huang J
Immun Inflamm Dis; 2021 Dec; 9(4):1596-1612. PubMed ID: 34432955
[TBL] [Abstract][Full Text] [Related]
26. A novel m6A/m5C/m1A score signature to evaluate prognosis and its immunotherapy value in colon cancer patients.
Liu J; Dou M; Liu X; Lu Y; Lu W
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11995-12012. PubMed ID: 37421455
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.
Wang Y; Zhu GQ; Tian D; Zhou CW; Li N; Feng Y; Zeng MS
BMC Cancer; 2022 Mar; 22(1):316. PubMed ID: 35331183
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the m6A/m1A/m5C/m7G-related regulators on the prognosis and immune microenvironment of glioma by integrated analysis of scRNA-seq and bulk RNA-seq data.
Yang L; Huang Z; Deng Y; Zhang X; Lv Z; Huang H; Sun Q; Liu H; Liang H; He B; Hu F
J Gene Med; 2024 Feb; 26(2):e3666. PubMed ID: 38391150
[TBL] [Abstract][Full Text] [Related]
29. Involvement of RNA methylation modification patterns mediated by m7G, m6A, m5C and m1A regulators in immune microenvironment regulation of Sjögren's syndrome.
Liu Y; Zhu J; Ding L
Cell Signal; 2023 Jun; 106():110650. PubMed ID: 36935085
[TBL] [Abstract][Full Text] [Related]
30. M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma.
Chen B; Yang Z; Lang Z; Tao Q; Zhang R; Zhan Y; Xu X; Zhu K; Zheng J; Yu Z; Yu S
BMC Cancer; 2022 Aug; 22(1):867. PubMed ID: 35941582
[TBL] [Abstract][Full Text] [Related]
31. N6-Methyladenosine-Related lncRNAs Are Potential Prognostic Biomarkers and Correlated With Tumor Immune Microenvironment in Osteosarcoma.
Zheng D; Yu L; Wei Z; Xia K; Guo W
Front Genet; 2021; 12():805607. PubMed ID: 35186011
[TBL] [Abstract][Full Text] [Related]
32. Identification of a novel m6A-related lncRNA pair signature for predicting the prognosis of gastric cancer patients.
Wang JM; Li X; Yang P; Geng WB; Wang XY
BMC Gastroenterol; 2022 Feb; 22(1):76. PubMed ID: 35189810
[TBL] [Abstract][Full Text] [Related]
33. Cross-Talk Between m
Song W; Ren J; Xiang R; Yuan W; Fu T
Front Immunol; 2022; 13():740960. PubMed ID: 35350786
[TBL] [Abstract][Full Text] [Related]
34. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.
He C; Zhu X; Kong F; Zhang X; Chai X; Zou C; Zhao D
Biomed Res Int; 2022; 2022():2747799. PubMed ID: 35711526
[TBL] [Abstract][Full Text] [Related]
35. Construction of an N6-methyladenosine lncRNA- and immune cell infiltration-related prognostic model in colorectal cancer.
Yu ZL; Zhu ZM
Protoplasma; 2022 Jul; 259(4):1029-1045. PubMed ID: 34734333
[TBL] [Abstract][Full Text] [Related]
36. The lncRNA epigenetics: The significance of m6A and m5C lncRNA modifications in cancer.
Cusenza VY; Tameni A; Neri A; Frazzi R
Front Oncol; 2023; 13():1063636. PubMed ID: 36969033
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the Divergent Gene Expression Landscapes of m6A/m5C/m1A Methylation Regulators in Hepatocellular Carcinoma Through Single-Cell and Bulk RNA Transcriptomic Analysis.
Liu HT; Rau CS; Liu YW; Hsieh TM; Huang CY; Chien PC; Lin HP; Wu CJ; Chuang PC; Hsieh CH
J Hepatocell Carcinoma; 2023; 10():2383-2395. PubMed ID: 38164510
[TBL] [Abstract][Full Text] [Related]
38. Construction of a Novel Signature and Prediction of the Immune Landscape in Soft Tissue Sarcomas Based on N6-Methylandenosine-Related LncRNAs.
Zhang L; Tang X; Wan J; Zhang X; Zheng T; Lin Z; Liu T
Front Mol Biosci; 2021; 8():715764. PubMed ID: 34733885
[No Abstract] [Full Text] [Related]
39. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
40. Novel methylation-related long non-coding RNA clinical outcome prediction method: the clinical phenotype and immune infiltration research in low-grade gliomas.
Li Y; Li X; Yu Z
Front Oncol; 2023; 13():1177120. PubMed ID: 37228500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]